Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Pfizer (NYSE:PFE) and maintained a $45 price target.
March 01, 2024 | 2:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating on Pfizer, with a $45 price target.
The reiteration of an Overweight rating and maintenance of a $45 price target by a reputable analyst could signal confidence in Pfizer's future performance, potentially influencing investor sentiment positively in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90